Alembic Pharma on Tuesday said its associate company Rhizen Pharmaceuticals AG’s product Umbralisib, which was licensed to TG Therapeutics, has received approval from the US health regulator the drug for the treatment of certain forms of cancer.
Copyright © 2024 | WordPress Theme by MH Themes
